Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
- 2020年04月24日 19:37:00
- テクノロジー
- JCN Newswire
- コメント
Efficient R&D Platform and Strong R&D Strength
The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.
The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.
Prominent Advantages of Core Products, Favored by the Capital Market
The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.
The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.
The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.
AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.
Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
グループ活動を一時休止するBE:FIRST三山凌輝、最新ショット公開に「オーラ半端ない」
ショートカット美少女の海空ちゃんのWebグラビア!無料で21P公開中!
【阪神】藤川監督、8勝目の村上頌樹に「1球1球の精度の高さは戻った」/一問一答
アンゴラ村長が「標準体型」写真集を発売♡リアルな魅力が話題に
フジテレビ佐々木恭子アナが「アナウンス局次長」に昇進へ、後任のアナウンス部長は渡辺和洋アナ
<1分で解説>税収の「上振れ」って何? 国の懐事情を解説
鈴木誠也、3戦ぶりの先制24号 自己最多タイ74打点 カブスは球団新8発大勝、最多貯金18
中村アン、赤を基調にしたあでやか浴衣 短冊に書いた願い事に「さすが!」の声
Aぇ!grou小島健が浴衣で願い事披露→なぜか「今年は寝ないです」宣言に
東京→大阪へ「一緒に出勤」百田夏菜子&芳根京子、豪華すぎる新幹線ツーショットの理由とは?
池袋・法律事務所で男性刺殺 容疑者は50歳同僚 「以前から恨み」
有村昆(44)の不倫未遂の相手とされるセクシー女優、ネットで「唯井まひろ」と噂されるも、本人は…
佐々木希が告白「多目的トイレ不倫」の夫渡部建と離婚の話し合い「すごい怖かったと思います」
「水着みたい」元NHKアナが“ピタピタ“私服ノースリ姿「妹がプレゼント…」に「センスよい」
「胸、大きくなってない?」元セクシー女優の上原亜衣、白ビキニ大胆ボディー披露「惚れてマウ」
元ジャンポケ斉藤慎二被告が告白、活動休止中に住んでいた県「ずっと休んでいた時間…」
あの、酔いつぶれた33歳女優を膝枕して家までタクシーで送っていた「優しい」
31歳女性タレント「それぐらいの覚悟じゃないと私ヤラないよ?」交際前のカラダの関係で本音吐露
給与天引きで初任給0円 ミャンマー人女性が「三ツ矢堂製麺」を提訴
43歳元グラドル、30歳で発症した病名明かす「不安がずっと襲ってきて…」
ガーシー、錦織圭の元モデル妻の暴露にネット騒然「なんで結婚したんだろ?」
有村昆(44)の不倫未遂の相手とされるセクシー女優、ネットで「唯井まひろ」と噂されるも、本人は…
小澤征悦と再婚した桑子真帆アナ(34)黒い過去が流出、衝撃の過去にネット騒然
再婚した旦那に不倫されてしまった飯島直子(51)衝撃的過ぎる黒歴史が発覚する事態に
山口真由氏は「しばらくお休みとなります」モーニングショー冒頭で羽鳥慎一アナが報告
二階堂ふみが結婚!?お相手が衝撃的過ぎてネット民「マジか・・・」
【7月21日まで】最大50%分のふるなびコインがもらえる「ふるなびメガ還元祭」3つのキャンペーンと参加方法
池袋・法律事務所で男性刺殺 容疑者は50歳同僚 「以前から恨み」
元フジ渡邊渚、ビキニ姿の大胆露出で表紙ジャック!「完成した誌面を見て毎度のことながら…」
ヒカル、浮気相手とのLINE流出にドン引きの声「キモすぎる」「吐きそう」

グループ活動を一時休止するBE:FIRST三山凌輝、最新ショット公開に「オーラ半端ない」
ショートカット美少女の海空ちゃんのWebグラビア!無料で21P公開中!
アンゴラ村長が「標準体型」写真集を発売♡リアルな魅力が話題に
【阪神】藤川監督、8勝目の村上頌樹に「1球1球の精度の高さは戻った」/一問一答
フジテレビ佐々木恭子アナが「アナウンス局次長」に昇進へ、後任のアナウンス部長は渡辺和洋アナ
<1分で解説>税収の「上振れ」って何? 国の懐事情を解説
鈴木誠也、3戦ぶりの先制24号 自己最多タイ74打点 カブスは球団新8発大勝、最多貯金18
中村アン、赤を基調にしたあでやか浴衣 短冊に書いた願い事に「さすが!」の声
Aぇ!grou小島健が浴衣で願い事披露→なぜか「今年は寝ないです」宣言に
東京→大阪へ「一緒に出勤」百田夏菜子&芳根京子、豪華すぎる新幹線ツーショットの理由とは?